BGI Genomics(SZ:300676)2025-01-21 11:00Financial Performance Expectations - The company expects a net loss attributable to shareholders of approximately -75,000 to -92,000 million RMB for the year 2024, compared to a profit of 9,290 million RMB in the previous year[2] - Estimated operating revenue for 2024 is projected to be between 380,000 and 400,000 million RMB, representing a decline of approximately 8.04% to 12.64% year-over-year[4] - Non-recurring gains and losses are expected to impact net profit by approximately -2,000 to 3,000 million RMB, compared to 160,000 RMB in the previous year[6] Business Growth Projections - Revenue from routine testing business is expected to grow over 6% year-over-year, while tumor and chronic disease prevention business is anticipated to grow over 15%, with colorectal cancer testing revenue expected to exceed 200 million RMB, a year-over-year increase of approximately 272%[5] Profitability Challenges - The company has faced significant declines in gross margins for some products due to price reductions and product structure adjustments, impacting overall profitability[5] - Credit impairment losses are expected to increase significantly in 2024 due to extended customer payment cycles, prompting the company to enhance credit control measures[5] - The company has increased R&D investment to expand product lines and innovate key products, which has impacted net profit due to high R&D expenses amid stagnant revenue growth[5] - Increased depreciation and amortization expenses from recent investments in office, R&D, and production facilities have raised overall operating costs[6] Strategic Adjustments - The company is strategically reducing its global production centers to optimize resource allocation, leading to asset impairment provisions and temporary operating losses[5] Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be disclosed in the 2024 annual report[7]